Free Trial
NASDAQ:SWKH

SWK Q3 2025 Earnings Report

SWK EPS Results

Actual EPS
$0.59
Consensus EPS
$0.34
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A

SWK Revenue Results

Actual Revenue
$13.72 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SWK Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
4:00PM ET

SWK Earnings Headlines

Important SpaceX PREDICTION
The biggest IPO in stock market history could go live as soon as June 12th — but trading legend Jon Najarian says investors are about to miss the real opportunity. A little-known FCC filing Elon quietly submitted earlier this year has caught Morgan Stanley's attention — and they estimate it could be worth $40 trillion. That's larger than Tesla, xAI, Starlink, X, Neuralink, and SpaceX combined.tc pixel
SWKHL: Attractive Baby Bond After The Merger, 9% Coupon
See More SWK Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SWK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SWK and other key companies, straight to your email.

About SWK

SWK (NASDAQ:SWKH) Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. This segment also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The Pharmaceutical Development segment provides customers pharmaceutical development, formulation, and manufacturing services, as well as formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. It also offers intellectual property licensing business. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.

View SWK Profile